D C Seldin
Overview
Explore the profile of D C Seldin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1395
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hovey B, Ward J, Soo Hoo P, OHara C, Connors L, Seldin D
Gene Ther
. 2011 May;
18(12):1150-6.
PMID: 21562591
Amyloid light chain (AL) amyloidosis is a rare hematologic disorder characterized by the accumulation of a misfolded monoclonal immunoglobulin (Ig) light chain (LC) as fibrillar protein deposits. Current treatments, including...
12.
Quillen K, Seldin D, Finn K, Sanchorawala V
Bone Marrow Transplant
. 2010 Oct;
46(7):976-80.
PMID: 20956955
High-dose melphalan and auto-SCT (HDM/SCT) induces hematological complete responses (HCRs) in 40% of patients with immunoglobulin light chain (AL) amyloidosis. However, relapses occur in 8% of patients who initially achieve...
13.
Girnius S, Seldin D, Quillen K, Dember L, Segal A, Sanchorawala V
Bone Marrow Transplant
. 2010 Apr;
46(1):161-2.
PMID: 20383204
No abstract available.
14.
Rosenzweig M, Seldin D, Remick D, Skinner M, Quillen K, Oran B, et al.
Bone Marrow Transplant
. 2009 May;
45(1):21-4.
PMID: 19421171
Aggressive treatment with high-dose i.v. melphalan followed by auto-SCT (HDM/SCT) is effective in inducing hematological and clinical remissions, and in extending survival in AL amyloidosis. Tandem cycles of HDM/SCT have...
15.
Dominguez I, Sonenshein G, Seldin D
Cell Mol Life Sci
. 2009 Apr;
66(11-12):1850-7.
PMID: 19387549
CK2 is a highly conserved tetrameric serine/ threonine kinase present in all eukaryotic organisms. It is constitutively active, and appears to be regulated by level of expression and activity, and...
16.
Sanchorawala V, Wright D, Quillen K, Finn K, Dember L, Berk J, et al.
Bone Marrow Transplant
. 2007 Jun;
40(6):557-62.
PMID: 17589534
Clinical outcomes of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation (HDM/SCT) are tightly linked to the achievement of a hematologic complete response (HCR). We conducted...
17.
Weichman K, Dember L, Prokaeva T, Wright D, Quillen K, Rosenzweig M, et al.
Bone Marrow Transplant
. 2006 Jul;
38(5):339-43.
PMID: 16862166
Light chain deposition disease (LCDD) is caused by a clonal plasma cell disorder in which fragments of monoclonal immunoglobulin light chains form non-fibrillary deposits in various tissues resulting in organ...
18.
Sanchorawala V, Blanchard E, Seldin D, OHara C, Skinner M, Wright D
Am J Hematol
. 2006 Jun;
81(9):692-5.
PMID: 16795060
AL amyloidosis, a systemic disorder characterized by widespread deposition of amyloid fibrils derived from monoclonal Ig light chains in organs and soft tissues, is typically caused by an underlying plasma...
19.
Sanchorawala V, Seldin D, Magnani B, Skinner M, Wright D
Bone Marrow Transplant
. 2005 Jul;
36(7):597-600.
PMID: 16044137
Serum free light-chain (FLC) concentrations were measured by a sensitive nephelometric immunoassay in 66 patients with AL amyloidosis before and after treatment with high-dose melphalan and autologous stem cell transplantation...
20.
Oran B, Malek K, Sanchorawala V, Wright D, Quillen K, Finn K, et al.
Bone Marrow Transplant
. 2005 Jan;
35(6):567-75.
PMID: 15665842
Treatment of patients with AL amyloidosis with high-dose melphalan and autologous peripheral blood stem cells (PBSC) produces hematologic remissions in approximately 40% of evaluable patients, accompanied by improvements in organ...